Investigational drug for treatment of Triple-Negative Breast Cancer

Trial ID:
IRB-24-8422
Mohammed Ali Jaloudi, MD

Inclusion Criteria

Patients must:

  • Be men or women 18 years of age or older
  • Have centrally confirmed Triple-Negative Breast Cancer
  • Have had a non pathologic complete response at surgery
  • Have had neoadjuvant chemotherapy

Exclusion Criteria

Patients must not:

  • Be pregnant or breastfeeding
  • Have the BRCA mutation
  • Have peripheral neuropathy
  • Have history of severe dry eye syndrome
  • Have active inflammatory bowel disease requiring immunosuppressive medication
  • Have uncontrolled, significant cardiovascular disease
  • Received prior treatment with a TROP2-directed ADC

Additional Info

All treatments and physician visits during the study will take place at Scripps Clinic Torrey Pines (Geisel Pavilion)

For more information search NCT06393374 at www.clinicaltrials.gov

Contact Info:

  • Clinical Research Services
  • crsleadership@scrippshealth.org